DoW Neurofibromatosis Synergistic Idea Award

The Neurofibromatosis Synergistic Idea Award is offered through the Defense Health Agency Contracting Activity under the Department of Defense as part of its broader Military Medical Research and Development portfolio. This program is aligned with federal priorities to advance scientific discovery and improve health outcomes for conditions that affect military personnel and the broader population. Neurofibromatosis is a group of genetic disorders that cause tumors to form on nerve tissue, and the Department of Defense has established a dedicated research program to accelerate progress in understanding, treating, and potentially curing these conditions. The purpose of this award mechanism is to support innovative, collaborative research projects that bring together multiple principal investigators to address complex challenges in neurofibromatosis research. The program specifically emphasizes synergistic approaches, requiring two or three principal investigators to contribute complementary expertise toward a unified research question or problem. The expectation is that collaboration across disciplines or perspectives will produce outcomes that would not be achievable through independent efforts. Applications must be grounded in scientific rigor and include preliminary or published data that demonstrate relevance to neurofibromatosis and feasibility of the proposed work. Funding under this opportunity is provided through grants, with an estimated total program funding of $6.4 million and approximately two awards anticipated. Each principal investigator within a collaborative team submits a separate application and receives an individual award, even when affiliated with the same organization. While specific award ceilings and floors are not explicitly defined in the available summary, the funding structure supports substantial research efforts across multiple institutions or departments. There is no cost sharing or matching requirement associated with this opportunity, allowing applicants to focus resources on research execution rather than financial contribution requirements. Eligibility for this opportunity is broadly defined as unrestricted, meaning that a wide range of entity types may apply, subject to any clarifications provided in the full announcement. This inclusivity allows participation from academic institutions, nonprofit organizations, private sector entities, and government-affiliated research bodies. The collaborative structure requires one initiating principal investigator, who is responsible for coordinating submission and administrative components, and one or two partnering principal investigators, each contributing substantively to the research aims. The application process requires each principal investigator to prepare and submit a complete application package. This includes documentation of preliminary data, detailed research plans, and justification of the collaborative synergy among investigators. While specific application components are detailed in the full announcement, the emphasis is placed on demonstrating scientific merit, innovation, and the added value of collaboration. Administrative coordination is centralized through the initiating principal investigator, but each partner must independently complete submission requirements. The application timeline indicates that the opportunity opened on June 25, 2026, and will close on September 22, 2026. Applications must be submitted by the closing date, and there is no indication of rolling submissions or recurring cycles. Applicants are encouraged to allow sufficient time for coordination among collaborating investigators, as each must submit separately. Questions or technical issues related to submission can be directed to the eBRAP Help Desk via phone or email, which serves as the primary contact point for applicant support. Evaluation of applications is expected to focus on the scientific merit of the proposal, the strength of preliminary data, and the degree to which the collaboration is truly synergistic rather than additive. Projects that clearly demonstrate how the integration of multiple perspectives advances the field of neurofibromatosis research are likely to be most competitive. Award notifications and project timelines are not explicitly stated in the summary but are typically aligned with federal grant review cycles. This opportunity represents a targeted investment in high-impact, collaborative biomedical research with the potential to significantly advance understanding and treatment of neurofibromatosis.

Ensure strong evidence of synergy between investigators and include robust preliminary data demonstrating feasibility and relevance to neurofibromatosis research